Lapatinib is primarily used in the treatment of HER2-positive breast cancer. It is often administered in combination with other drugs, such as capecitabine or letrozole, to enhance its efficacy. While its primary indication is for breast cancer, ongoing research is exploring its potential in other cancers such as gastric cancer and non-small cell lung cancer.
